Headquartered in Foster City, CA·Fiscal year ends December·NASDAQ: GILD·gilead.com
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines to prevent and treat life-threatening diseases. Its therapeutic areas are HIV, viral hepatitis and other liver diseases, COVID-19, cancer and inflammation.
HIV is its largest business, accounting for the bulk of product sales. Key HIV products include:
- Biktarvy and Descovy
- Genvoya and Odefsey
- Revenue share from Symtuza
- Yeztugo, the twice-yearly lenacapavir for HIV prevention (PrEP)
- Bixlenvo, a newly FDA-approved bictegravir/lenacapavir single-tablet regimen
Its Liver Disease portfolio includes Livdelzi (seladelpar) for primary biliary cholangitis, Epclusa and other HCV medicines, Vemlidy and Viread for hepatitis B, and Hepcludex. In Oncology, Gilead markets Trodelvy, a Trop-2 directed ADC approved in first-line metastatic triple-negative breast cancer. Its Kite unit sells the CAR-T cell therapies Yescarta and Tecartus. Other products include Veklury (remdesivir) for COVID-19 and AmBisome.
The company is building an inflammation pipeline, including oral alpha-4-beta-7 inhibitor emvistegrast and an oral IL-23R inhibitor program being acquired from PepStar. In 2026 it expanded through acquisitions and licensing deals including Arcellx, Tubulis and Ouro Medicines. Gilead operates in more than 35 countries. It generates most of its product sales in the U.S., with the remainder from Europe and the rest of the world. Updated
51 stocks printed fresh 52-week highs this week, and the leadership is energy plus big biotech: Cheniere cleared its prior peak by 11.7%, with Regeneron, Eli Lilly and Gilead all stretching more than 8% past theirs.
Intel opened down 29%, a one-day drop of a size this name almost never posts, while the top of the board belongs entirely to pharma, led by Regeneron. Four of the five biggest decliners fell by double digits.
Management has now raised full-year product sales guidance three times this year, a cumulative $1.6 billion increase since January, on 18% HIV sales growth. New twice-yearly PrEP drug Yeztugo is the engine behind it.
“Gilead delivered an exceptional third quarter, with our strongest year-over-year base business growth in more than a decade, reflecting the strength, breadth and durability of our business.
Gilead's CEO is staking the quarter on a decade-best base business growth rate, and it lands as long-acting HIV rivals push harder into its core franchise. The stock barely moved on it, which means the market wants the follow-through before repricing.
“Our performance enabled us to raise our full year base business revenue guidance again this quarter, bringing the total increase to $1.6 billion since the start of 2026. Our HIV business grew 18% and HIV prevention sales nearly doubled year-over-year.
Third guidance raise of the year for Gilead, and the prevention franchise is now doing the heavy lifting as Yeztugo scales. CEO Daniel O'Day framed the Q3 report around a base business that keeps outrunning the company's own forecasts.
New 52-week high$158.69+0.8% vs prior high · 2026-10-15
Gilead Sciences set a new 52-week high at $158.69, clearing its October 15 peak by 0.84% and making this the second record in under two weeks. The $196.8 billion biotech is now roughly a third above where it traded a year ago.
Gilead is sending shareholders about $1.02 billion in cash, 82 cents a share, landing September 29 and dwarfing every other payment today. Xcel Energy, Ares Capital, T. Rowe Price and Valley National Bancorp round out the biggest checks.
A red ink EPS figure usually spells trouble for retirees counting on a payout. Gilead's loss traces back to one strange quarter, and a single cash metric reveals whether the dividend checks…
Eli Lilly's EPS estimate collapsed by a third in just 30 days, Merck faces a comparison it cannot repeat, and Gilead is burning through cash fast. Three pharma giants report Thursday, and…
When a drugmaker's top product loses patent protection, the dividend usually takes the hit. Four pharma giants are each betting on newer drugs to fill the gap, but how close each one…
Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway. The five names on this list have already replaced their fading blockbusters with something…
Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the…
Gilead's quarterly dividend keeps growing and its HIV cash machine runs hot, but the whole enterprise depends on a single blockbuster drug with a patent expiration already penciled onto a calendar a…
Wall Street analysts are making bold moves on Tuesday, shaking up ratings for some of the biggest names in tech, biotech, and retail in ways that could catch investors off guard. Find…
Both Pfizer and Gilead Sciences just flashed the same ominous technical warning while trading below analyst fair value, but the reasons behind each selloff tell very different stories about which one actually…
On CNBC’s Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave…
Pre-Market Stock Futures: Futures are trading mixed as we get ready to start the first full week of trading for the third quarter, as traders and investors return from the long 4th…
The phrase sounds almost impossible: a short squeeze involving index funds. After all, index funds are designed to be passive, rules-based buyers, not active traders caught on the wrong side of a…
Moderna (NASDAQ:MRNA | MRNA Price Prediction) is back in the headlines after ripping 63.17% higher year to date on a surprise Q1 revenue triple and renewed pipeline excitement. But the underlying story…
Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR…
Josh Brown, CEO of Ritholtz Wealth Management, made a pointed claim on CNBC’s Halftime Report this week about large-cap biotech: “These are growth stocks where you don’t have to worry about disruption.…
Wall Street is drawing fresh lines across the large-cap biopharma landscape. Jefferies initiated coverage on Gilead Sciences Inc. (NASDAQ:GILD | GILD Price Prediction) with a Buy rating and a $180 price target,…
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines to prevent and treat life-threatening diseases. Its therapeutic areas are HIV, viral hepatitis and other liver diseases, COVID-19, cancer and inflammation.
What is the GILD stock price target?
24/7 Wall St.'s 12-month price target for GILD is $189.92, rated Buy. The Wall Street consensus target is $172.50. GILD price prediction →
